soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM The SOUL Study - by

Understanding how to support your body's natural GLP-1 production through dietary and lifestyle modifications provides a foundation for metabolic health, though these approaches should not replace medical therapy where indicated

Something physical changes in the brain that makes it hard for people to lose weight and to comply with the diet, and thats why medication appears to be necessary in this situation. Such efforts are also important given the relationship between ethnicity and obesity-related diseases

Does a platform being well-known mean it's safe for GLP-1 treatment

It also improves insulin sensitivity and glucose disposal, which matters with IGF-1 LR3 given the hypoglycemia risk

Dining out/travel an ordering framework that keeps protein and portions consistent